GridAI Technologies (GRDX) Poised at Convergence of Electrification, EV Growth and AI Demand

About this update from Gridai Technologies Corp.

LOS ANGELES, CA - February 23, 2026 ( NEWMEDIAWIRE ) - GridAI Technologies (NASDAQ: GRDX) , a company operating at the intersection of artificial intelligence and energy infrastructure, is positioned for opportunity as the power grid has become a central battleground for the next phase of AI growth. An article discussing this reads, "The company is developing grid and power-management software aimed at hyperscale AI data center campuses. Its core proposition is that the limiting factor for AI infrastructure is no longer only compute capacity, but the ability to control and optimize energy at scale This challenge is structural. Modern grids were designed for predictable demand patterns and centralized generation. AI data centers do not conform to that model. They operate continuously, draw large and variable loads, and increasingly cluster in regions where grid capacity is already strained. At the same time, electric vehicles, electrification of industry, and distributed energy resources are adding new layers of volatility Rather than building power plants or transmission lines, the company focuses on orchestration software that allows existing assets to operate more flexibly. Its systems coordinate energy flows between grid connections, on-site generation such as reciprocating engines, battery energy storage systems (BESS'), and, in some cases, renewable inputs like solar." To view the full article, visit https://ibn.fm/QhL65 About GridAI Technologies Corp. GridAI Technologies is a publicly listed, diversified technology and life sciences company on the Nasdaq. The company is advancing opportunities at the intersection of artificial intelligence and energy infrastructure following its acquisition of Grid AI, Inc. In addition to its GridAI operations, the company (formerly Entero Therapeutics Inc.) continues to advance its late clinical-stage biopharmaceutical program focused on the development of targeted, non-systemic therapies for gastrointestinal ("GI") diseases. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

View stock analysis, news, and events for Gridai Technologies Corp.